A.Z. SHARAFEEV¹, A.F. KHALIRAKHMANOV¹, E.Kh. KHARISOVA²

¹Kazan State Medical Academy, 36 Butlerov Str., Kazan, Russian Federation, 420012

²Kazan State Medical University, 49 Butlerov Str., Kazan, Russian Federation, 420012

Sharafeev A.Z. ― D. Med. Sc., Head of the Department of Cardiology, Roentgen Endovascular and Cardiovascular Surgery, tel. (843) 233-30-49, e-mail: aidarch@mail.ru

Khalirakhmanov A.F. ― applicant of the Department of Cardiology, Roentgen Endovascular and Cardiovascular Surgery, tel. +7-929-722-33-34, e-mail: ai.bolit@mail.ru

Kharisova E.Kh. ― D. Med. Sc., internist of the Department of Cardiology, tel. +7-917-292-50-17, e-mail: enzhe-h@mail.ru

Atherosclerotic renal artery stenosis is a very common lesion manifesting a variety of clinical syndromes such as hypertension and ischemic nephropathy. The main treatment for this group of patients is endovascular revascularization of the renal arteries. The recent randomized trials reduced the enthusiasm for revascularization of renal artery stenosis in general, but many clinicians recognize the need for renal artery stenting in appropriately selected patients. This article highlights the main causes of stenoses and occlusions of the renal arteries, renal compensatory opportunities that arise in response to a decrease in blood flow? And describes the recent randomized trials in this area. Also in the article shows the role of evaluating the viability of kidney and compensatory possibilities in the selection of patient groups, which need the endovascular revascularization.

Key words: ishemic nefropathy, renal artery stenosis, renal arteries stenting, renovascular hypertension.

REFERENCES

1. Sharafeev A.Z., Khalirakhmanov A.F., Sharafutdinov B.M. Modern state-of renal artery stenting. Prakticheskaya meditsina, 2014, 20, pp. 24-32 (in Russ.).
2. Mark P.B., Schiffrin E.L., Jennings G.L., et al. Renovascular hypertension: to stent or not to stent?. Hypertension, 2014, 64, pp. 1165-1168.
3. Textor S.C. Attending rounds: a patient with accelerated hypertension and an atrophic kidney. Clin. J. Am. Soc. Nephrol, 2014, 9, pp. 1117-1123.
4. Herrmann S.M., Saad A., Textor S.C. Management of atherosclerotic renovascular disease after Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL). Nephrol Dial Transplant, 2015, 30, pp. 366-375.
5. Bax L., Woittiez A-J.J., Kouwenberg H.J. et al. Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial. Ann. Intern. Med, 2009, no. 150, pp. 840-848.
6. Kotliar C., Juncos L., Inserra F. et al. Local and systemic cellular immunity in early renal artery atherosclerosis. Clin. J. Am. Soc. Nephrol, 2012, 7, pp. 224-230.
7. De Ciuceis C., Rossini C., La Boria E. et al. Immune mechanisms in hypertension. High Blood Press Cardiovasc Prev, 2014, 21, pp. 227-234.
8. Chrysant G.S., Bates M.C., Sullivan T.M. et al. Proper patient selection yields significant and sustained reduction in systolic blood pressure following renal artery stenting in patients with uncontrolled hypertension: long-term results from the HERCULES trial. J. Clin. Hypertens, 2014, 16, pp. 497-503.
9. De Bruyne B., Manoharan G., Pijls N.H.J. et al. Assessment of renal artery stenosis severity by pressure gradient measurements. J. Am. Coll Cardiol, 2006, 48, pp. 1851-1855.
10. Mangiacapra F., Trana C., Sarno G. et al. Translesional pressure gradients to predict blood pressure response after renal artery stenting in patients with renovascular hypertension. Circ Cardiovasc. Interv, 2010, 3, pp. 537-542.
11. White C.J. The «chicken little» of renal stent trials: the CORAL trial in perspective. JACC Cardiovasc. Interv, 2014, 7, pp. 111-113.
12. Cooper C.J., Murphy T.P., Cutlipetal D.E. Stenting and medical therapy for atherosclerotic renal artery stenosis. N. Engl. J. Med, 2014, pp. 370, 13–22.
13. Lerman L.O., Textor S.C. Gained in translation: protective paradigms for the poststenotic kidney. Hypertension, 2015, 65, pp. 976-982.
14. Parekh D.J., Weinberg J.M., Ercole B. et al. Tolerance of the human kidney to isolated controlled ischemia. J. Am. Soc. Nephrol, 2013, 24, pp. 506-517.
15. Eirin A., Ebrahimi B., Zhang X. et al. Mitochondrial protection restores renal function in swine atherosclerotic renovascular disease. Cardiovasc. Res, 2014, 103, pp. 461-472.
16. Chrysochou C., Foley R.N., Young J.F. et al. Dispelling the myth: the use of reninangiotensin blockade in atheromatous renovascular disease. Nephrol Dial. Transplant, 2012, 27, pp. 1403-1409.